Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Conditions
Interventions
Alirocumab
Statins
+5 more
Locations
119
United States
Investigational Site Number 840-163
Little Rock, Arkansas, United States
Investigational Site Number 840-141
Fresno, California, United States
Investigational Site Number 840-152
Huntington Beach, California, United States
Investigational Site Number 840-115
La Jolla, California, United States
Investigational Site Number 840-118
Los Angeles, California, United States
Investigational Site Number 840-106
Northridge, California, United States
Start Date
March 15, 2016
Primary Completion Date
March 22, 2017
Completion Date
May 15, 2017
Last Updated
May 1, 2018
NCT07238556
NCT06314919
NCT07162441
NCT06935513
NCT06932705
NCT06568471
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions